CRISPR‐based curing and analysis of metabolic burden of cryptic plasmids in Escherichia coli Nissle 1917
- 14 May 2019
- journal article
- research article
- Published by Wiley in Engineering in Life Sciences
- Vol. 19 (6) , 478-485
Abstract
E. coli Nissle 1917 (EcN) has long been used as an over‐the‐counter probiotic and has shown potential to be used as a live biotherapeutic. It contains two stably replicating cryptic plasmids, pMUT1, and pMUT2, the function of which is unclear but the presence of which may increase the metabolic burden on the cell, particularly in the context of added recombinant plasmids. In this work, we present a clustered regularly interspaced short palindromic repeats‐Cas9‐based method of curing cryptic plasmids, producing strains cured of one or both plasmids. We then assayed heterologous protein production from three different recombinant plasmids in wild‐type and cured EcN derivatives and found that production of reporter proteins was not significantly different across strains. In addition, we replaced pMUT2 with an engineered version containing an inserted antibiotic resistance reporter gene and demonstrated that the engineered plasmid was stable over 90 generations without selection. These findings have broad implications for the curing of cryptic plasmids and for stable heterologous expression of proteins in this host. Specifically, curing of cryptic plasmids may not be necessary for optimal heterologous expression in this host.Keywords
Funding Information
- Ministry of Higher Education, Malaysia
- National Institute of General Medical Sciences (1R21GM131189‐01)
This publication has 36 references indexed in Scilit:
- Draft Genome Sequence of Escherichia coli Strain Nissle 1917 (Serovar O6:K5:H1)Microbiology Resource Announcements, 2013
- Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin ProteinApplied and Environmental Microbiology, 2012
- Enhanced Wound Healing by Recombinant Escherichia coli Nissle 1917 via Human Epidermal Growth Factor Receptor in Human Intestinal Epithelial Cells: Therapeutic Implication Using Recombinant ProbioticsInfection and Immunity, 2012
- Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)BMC Complementary and Alternative Medicine, 2010
- Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88International Journal of Medical Microbiology, 2009
- The non-pathogenicEscherichia colistrain Nissle 1917 – features of a versatile probioticMicrobial Ecology in Health and Disease, 2009
- Probiotic Escherichia coli Nissle 1917 Versus Placebo for Treating Diarrhea of Greater Than 4 Days Duration in Infants and ToddlersThe Pediatric Infectious Disease Journal, 2008
- NonpathogenicEscherichia coliStrain Nissle 1917 Inhibits Signal Transduction in Intestinal Epithelial CellsInfection and Immunity, 2008
- The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlersEuropean Journal of Pediatrics, 2007
- A Greedy Algorithm for Aligning DNA SequencesJournal of Computational Biology, 2000